C. difficile 위험도


Moderate or severe pneumoniaNeutropenic feverMild or moderate UTISevere UTIModerate or severe SSTIComplicated intraabdominal infection1-2 g IV q8-12h x10d2 g IV q8h0.5-1 g IV q12h x7-10d2 g IV q12h x10d2 g IV q12h x10d2 g IV q12h x7-10d

UTI, pneumonia, uncomplicated SSTINeutropenic feverSafety and efficacy in pediatric patients <2m of age have not been established50 mg/kg IV q12h50 mg/kg IV q8h

No dose adjustment

CrCl >60CrCl 30-60CrCl 11-29CrCl <11HDCRRTCAPDNo dose adjustmentRecommended dose IV q24hRecommended dose IV q24hRecommended dose IV q24h1 g q24h (+ extra 1 g AD)2 g q12-24hRecommended dose IV q48h

General Information

Broad spectrum antimicrobial with gram-positive and gram-negative coverage including Pseudomonas.

Used especially nosocomial infections involving resistant organisms.

Monitor WBC count, renal function, prothrombin time.


  • Direct Coombs test positive

  • Rash

  • Diarrhea

  • Hypophosphatemia

  • Increased liver enzymes


  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Clostridium difficile colitis

  • Anaphylaxis

  • Encephalopathy

  • Aphasia

  • Neurotoxicity

  • Myoclonus

  • Nonconvulsive status epilepticus

  • Seizure

  • Warfarin - increased risk of bleeding

  • Cholera vaccine, live

Antimicrobial class: 4th Generation Cephalosporin

Pregnancy category: B

Average serum half life: 2 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Therapeutic

Biliary penetration: Moderate


  • Dosage adjustment required in patients with renal impairment (CrCl <60 mL/min).

  • Dosage adjustment or discontinuation may be necessary if neurotoxic events occur.

  • Discontinuation may be necessary in Clostridium difficile-associated diarrhea.

  • Monitoring and dosage adjustment may be necessary in elderly patients, especially with renal dysfunction.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.